Kybella / Belkyra

Record type

Source-linked family profile

Recorded maker

AbbVie (Allergan Aesthetics)

Classification

Fat-dissolving injectable

Material identity

deoxycholic acid

Snapshot date

14 August 2026

Manufacturer and category are catalogue fields. They are not, by themselves, a regulatory classification or verification of the exact marketed presentation.

Names and markets

Aliases in this profile

• Kybella

  United States brand name in the attached source

• Belkyra

  Canadian brand name in the attached source

Alias grouping supports discovery. It does not claim that regional products, labels, units, formulations, or authorised uses are interchangeable.

Product names and regulatory context do not travel automatically between countries. Each row below is limited to its named source market.

1. Manufacturer

   1. Kybella official site

   Allergan Aesthetics, an AbbVie company · United States

   Open source ↗

   Supports: United States product and safety-information context.

2. Approved label

   2. KYBELLA — current United States drug label

   U.S. National Library of Medicine (DailyMed) · United States

   Open source ↗

   Supports: The current US Kybella prescription-drug identity, label context, dosage form, and deoxycholic-acid naming.

3. Regulator

   3. BELKYRA — Drug Product Database record

   Health Canada · Canada

   Open source ↗

   Supports: The Canadian Belkyra product identity, marketed status in that database, prescription schedule, dosage form, company, and deoxycholic-acid ingredient record.

1. 1

   Market-scoped names

   Kybella and Belkyra are separately documented US and Canadian deoxycholic-acid product identities in this discovery profile.

   Scope: The grouping is for identity discovery only and does not assert presentation or label equivalence.

   Evidence: KYBELLA — current United States drug labelEvidence: BELKYRA — Drug Product Database record
2. 2

   Material / active name

   Both attached official product records name deoxycholic acid.

   Scope: Shared ingredient naming does not establish interchangeability, dosing, or authorised use across jurisdictions.

   Evidence: KYBELLA — current United States drug labelEvidence: BELKYRA — Drug Product Database record

Use boundary

What this record does not establish

• Regulatory statusOnly within a source's named jurisdiction; family-profile review does not establish status elsewhere.
• Authenticity or supply chainA catalogue name cannot authenticate an individual box, lot, or seller.
• Clinical suitabilityNo product selection, patient assessment, dose, protocol, or injection technique is provided.
• Availability or equivalenceNames, formulations, units, and presentations can vary by market and over time.